8-K: Matinas BioPharma Announces Positive Safety Data for Oral LNC-Docetaxel in Preclinical Study

Matinas BioPharma's oral LNC-docetaxel formulation demonstrated a significantly improved safety profile compared to IV-docetaxel in a preclinical study, with mice maintaining body weight while receiving a higher dose.

Summary

• Matinas BioPharma announced positive results from an in vivo study of its oral lipid nanocrystal (LNC) formulation of docetaxel in healthy mice.
• The study compared oral LNC-docetaxel to intravenous (IV) docetaxel, a common chemotherapy drug known for its toxicity.
• Mice treated with IV-docetaxel experienced an average peak weight loss of 20%, indicating significant toxicity.
• In contrast, mice treated with oral LNC-docetaxel maintained their body weight, showing no significant difference from the control group.
• The total amount of docetaxel administered with the oral LNC formulation was more than 8 times greater than with IV-docetaxel.
• The daily dose of oral LNC-docetaxel was 50% higher, and the total amount of drug administered was 3.5 times greater, than in a previous study that showed comparable anti-tumor activity to IV-docetaxel.
• The company believes the LNC technology protects the body from the drug until it reaches tumor cells, reducing toxicity.
• Matinas plans to evaluate higher doses of oral LNC-docetaxel in additional tumor models, including those that have not responded well to docetaxel.

Sentiment

Score: 8

Explanation: The document presents very positive preclinical results for the oral LNC-docetaxel formulation, showing a significant improvement in safety compared to IV-docetaxel. The company is also planning to evaluate higher doses and other chemotherapies, indicating a strong potential for future development. However, the company's need for additional capital and the development stage of its products temper the overall sentiment.

Positives

• The oral LNC-docetaxel formulation demonstrated a significantly improved safety profile compared to IV-docetaxel.
• Mice treated with oral LNC-docetaxel maintained their body weight, indicating reduced toxicity.
• The study used a higher dose of oral LNC-docetaxel than previous studies, with no significant toxicity.
• The LNC technology may enable oral delivery of toxic chemotherapies with reduced side effects.
• The results suggest a broader therapeutic index for oral LNC-docetaxel.

Negatives

• One mouse in the IV-docetaxel group died during the study due to toxicity.
• IV-docetaxel caused significant weight loss in mice, highlighting its known toxicity.

Risks

• The company's product candidates are all in a development stage and are not available for sale or use.
• The company needs to obtain additional capital to meet its liquidity needs and complete clinical trials.
• There are uncertainties inherent in clinical testing and obtaining regulatory approvals.
• The company faces competition and changes in the regulatory landscape.
• The company's ability to protect its intellectual property is a risk.

Future Outlook

Matinas BioPharma plans to evaluate higher doses of oral LNC-docetaxel in additional tumor models, including those that have not historically responded well to docetaxel therapy, and explore potential improvements in the therapeutic indices of other toxic chemotherapies. The company also plans to continue development of its lead product candidate, MAT2203.

Management Comments

• James J. Ferguson, M.D., Chief Medical Officer of Matinas, stated that the data show how the oral LNC-docetaxel formulation can dramatically reduce the well-recognized toxicity of IV-docetaxel.
• He also noted that the unique phosphatidylserine composition of LNCs allows for selective tumor targeting and delivery.

Industry Context

The announcement is significant as it addresses a major challenge in cancer treatment: the toxicity of chemotherapy drugs. The development of an oral formulation of docetaxel with reduced toxicity could be a major advancement in oncology. This aligns with the industry trend of developing targeted therapies with improved safety profiles.

Comparison to Industry Standards

• The study results are compared to the standard IV administration of docetaxel, which is known for its significant toxicity, including weight loss.
• The results are also compared to a previous study by Matinas BioPharma that demonstrated anti-tumor activity of oral LNC-docetaxel comparable to IV-docetaxel in a mouse melanoma model.
• The company is aiming to improve on the current standard of care for docetaxel, which is typically administered intravenously and has significant side effects.
• Other companies are also working on improving drug delivery methods to reduce toxicity, but Matinas' LNC platform is unique in its approach to oral delivery and tumor targeting.

Stakeholder Impact

• Shareholders may view the positive preclinical results as a positive development for the company's technology and future prospects.
• Employees may be encouraged by the progress of the company's research and development efforts.
• Patients may benefit from the development of safer and more effective cancer treatments.
• The company's suppliers and partners may see potential for future collaborations and business opportunities.

Next Steps

• Matinas plans to evaluate higher doses of oral LNC-docetaxel in additional tumor models.
• The company will explore potential improvements in the therapeutic indices of other toxic chemotherapies.
• Matinas will continue development of its lead product candidate, MAT2203.
• The company will host a conference call on March 27, 2024, to discuss financial results and provide a business update.

Key Dates

Keywords

LNC, docetaxel, oral delivery, chemotherapy, oncology, toxicity, lipid nanocrystal, drug delivery, cancer, Matinas BioPharma